+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

In-vitro Colorectal Cancer Screening Tests Market Size, Share & Trends Analysis Report By Test Type (Fecal Occult Blood Tests, Biomarker Tests, CRC DNA Screening Tests), By Region, And Segment Forecasts, 2023 - 2030

  • PDF Icon

    Report

  • 129 Pages
  • September 2023
  • Region: Global
  • Grand View Research
  • ID: 5893306
Description Jump to:
The global in-vitro colorectal cancer screening tests market size is expected to reach USD 1.12 billion by 2030, expandingat a CAGR of 3.02% from 2023 to 2030. Rising number of novel screening models to combat the increasing incidences of colon and rectal malignancy cases is the major factor influencing the market growth. The emergence of newly developed genetic and biomarker tests such as tumor M2-PK stool tests and methylated gene testing is anticipated to drive the adoption rate of tumor diagnostic models.

The increasing incidence of colorectal malignancy is a significant driver for the growth of the segment. For example, according to data released by the National Cancer Center Japan in June 2022, it was projected that there would be approximately 1, 019, 000 new cases of cancer in Japan in 2022, with Colorectal Cancer (CRC) accounting for an estimated 158, 200 new cases. Similarly, data updated by Cancer Australia in August 2022 indicated that 15, 713 new cases of CRC were expected to be diagnosed in Australia in 2022, with 8, 300 cases among males and 7, 413 cases among females. As a result, the increasing prevalence of colorectal malignance is anticipated to drive the demand for colonoscopy devices.

The implementation of various initiatives by public organizations to promote screening has positively impacted the demand for in-vitro CRC screenings. For instance, according to reports from Cancer.org, healthcare systems in California continued to provide FIT kits (fecal immunochemical tests) during the months of April and May 2020, and the response rates for FIT remained high despite the onset of the COVID-19 pandemic. Additionally, the European Cancer community has mobilized its resources to evaluate, address, and mitigate the adverse effects of COVID-19 on screening. These efforts have contributed to the sustained demand for in-vitro screening tests.

Furthermore, market growth is expected to be driven by the increasing number of product launches by major market players. These product launches are aimed at providing access to technologically advanced and innovative products. For instance, Pillar Biosciences, Inc. received FDA approval for the ONCO/Reveal Dx Lung & Colon Cancer Assay (O/RDx-LCCA) in July 2021 for the detection of CRC.

In-vitro Colorectal Cancer Screening Tests Market Report Highlights

  • Based on test type, fecal occult blood testing segment held the largest share of the market in 2022 due to their wider usage and easy applicability by large customer base
  • Among FOB test segment, immuno-FOB ELISA test held a significant share in 2022, as immunological testing offers more accuracy than conventional guaiac FOB stool test
  • Biomarker tests are expected to gain revenue share over the forecast period due to the emergence of noninvasive screening procedures
  • Tumor M2-PK stool test generated maximum revenue in 2022 due to recent product introduction such as ScheBo Tumor M2-PK Stool Test by ScheBo Biotech AG
  • In CRC DNA screening test vertical, panel DNA tests are gaining ground as these are advanced genetic screening tests, thus contributing the maximum revenue share
  • North America held the largest share of the market in 2022, which can be attributed to high adoption rate of these products in clinical workflow for detection of melanoma
  • Key players operating in the market include Abbott Laboratories; Quest Diagnostics; Siemens AG; Randox Laboratories; Kyowa Medex; and GeneNews and are constantly focusing on product launches and geographical expansion to gain higher share in the market
  • In December 2022, Guardant Health, Inc., a company based in the United States, reported positive findings from the ECLIPSE study. This extensive study involved more than 20, 000 patients and aimed to assess the effectiveness of Guardant Health's blood test in detecting colorectal cancer (CRC) in average-risk adults

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Segment Definitions
1.1.1.1. Test type segment
1.2. Regional Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
1.4.1. Objective - 1
1.4.2. Objective - 2
1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. Internal Database
1.6.3. Secondary Sources
1.6.4. Primary research
1.7. Information or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Test Type Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing incidence of colon and rectal cancers
3.2.1.2. Growing accuracy of colorectal cancer screening by use of genetic testing
3.2.1.3. Presence of a number of colorectal cancer screening products in pipeline
3.2.2. Market Restraint Analysis
3.2.2.1. Pending investigational evidence for certain genetic screening tests
3.2.2.2. Difficulty to undertake CRC screening tests to encompass the entire
3.2.2.3. Lack of cancer screening guideless in Asia Pacific region
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
Chapter 4. Test Type Business Analysis
4.1. In-vitro Colorectal Cancer Screening Tests Market: Test Type Movement Analysis
4.2. Fecal Occult Blood Tests
4.2.1. Fecal Occult Blood Tests Market, 2018 - 2030 (USD Million)
4.2.2. Guaiac FOB Stool Test
4.2.2.1. Guaiac FOB Stool Test Market, 2018 - 2030 (USD Million)
4.2.3. Immuno-FOB Agglutination Test
4.2.3.1. Immuno-FOB Agglutination Test Market, 2018 - 2030 (USD Million)
4.2.4. Lateral Flow Immuno-FOB Test
4.2.4.1. Lateral Flow Immuno-FOB Test Market, 2018 - 2030 (USD Million)
4.2.5. Immuno-FOB ELISA Test
4.2.5.1. Immuno-FOB ELISA Test Market, 2018 - 2030 (USD Million)
4.3. Biomarker Tests Market
4.3.1. Biomarker Tests Market, 2018 - 2030 (USD Million)
4.3.2. Tumor M2-PK Stool Test
4.3.2.1. Tumor M2-PK Stool Test Market, 2018 - 2030 (USD Million)
4.3.3. Transferrin Assays
4.3.3.1. Transferrin Assays Market, 2018 - 2030 (USD Million)
4.3.4. Immuno-FOB ELISA Test
4.3.4.1. Immuno-FOB ELISA Test Market, 2018 - 2030 (USD Million)
4.4. CRC DNA Screening Tests
4.4.1. CRC DNA Screening Tests Market, 2018 - 2030 (USD Million)
4.4.2. Methylated Gene Testing
4.4.2.1. Methylated Gene Testing Market, 2018 - 2030 (USD Million)
4.4.3. Panel DNA Tests
4.4.3.1. Panel DNA Tests Market, 2018 - 2030 (USD Million)
Chapter 5. Regional Business Analysis
5.1. In-vitro Colorectal Cancer Screening Tests Market Share By Region, 2022 & 2030
5.2. North America
5.2.1. SWOT Analysis
5.2.2. North America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.2.3. U.S.
5.2.3.1. Key Country Dynamics
5.2.3.2. Target Disease Prevalence
5.2.3.3. Competitive Scenario
5.2.3.4. Regulatory Framework
5.2.3.5. U.S. In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.2.4. Canada
5.2.4.1. Key Country Dynamics
5.2.4.2. Target Disease Prevalence
5.2.4.3. Competitive Scenario
5.2.4.4. Regulatory Framework
5.2.4.5. Canada In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.3. Europe
5.3.1. SWOT Analysis
5.3.2. Europe In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.3.3. UK
5.3.3.1. Key Country Dynamics
5.3.3.2. Target Disease Prevalence
5.3.3.3. Competitive Scenario
5.3.3.4. Regulatory Framework
5.3.3.5. UK In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.3.4. Germany
5.3.4.1. Key Country Dynamics
5.3.4.2. Target Disease Prevalence
5.3.4.3. Competitive Scenario
5.3.4.4. Regulatory Framework
5.3.4.5. Germany In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.3.5. France
5.3.5.1. Key Country Dynamics
5.3.5.2. Target Disease Prevalence
5.3.5.3. Competitive Scenario
5.3.5.4. Regulatory Framework
5.3.5.5. France In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.3.6. Italy
5.3.6.1. Key Country Dynamics
5.3.6.2. Target Disease Prevalence
5.3.6.3. Competitive Scenario
5.3.6.4. Regulatory Framework
5.3.6.5. Italy In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.3.7. Spain
5.3.7.1. Key Country Dynamics
5.3.7.2. Target Disease Prevalence
5.3.7.3. Competitive Scenario
5.3.7.4. Regulatory Framework
5.3.7.5. Spain In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.3.8. Sweden
5.3.8.1. Key Country Dynamics
5.3.8.2. Target Disease Prevalence
5.3.8.3. Competitive Scenario
5.3.8.4. Regulatory Framework
5.3.8.5. Sweden In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.3.9. Norway
5.3.9.1. Key Country Dynamics
5.3.9.2. Target Disease Prevalence
5.3.9.3. Competitive Scenario
5.3.9.4. Regulatory Framework
5.3.9.5. Norway In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.3.10. Denmark
5.3.10.1. Key Country Dynamics
5.3.10.2. Target Disease Prevalence
5.3.10.3. Competitive Scenario
5.3.10.4. Regulatory Framework
5.3.10.5. Denmark In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.3.11. Russia
5.3.11.1. Key Country Dynamics
5.3.11.2. Target Disease Prevalence
5.3.11.3. Competitive Scenario
5.3.11.4. Regulatory Framework
5.3.11.5. Russia In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.3.12. Netherlands
5.3.12.1. Key Country Dynamics
5.3.12.2. Target Disease Prevalence
5.3.12.3. Competitive Scenario
5.3.12.4. Regulatory Framework
5.3.12.5. Netherlands In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.4. Asia Pacific
5.4.1. SWOT Analysis
5.4.2. Asia Pacific In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.4.3. Japan
5.4.3.1. Key Country Dynamics
5.4.3.2. Target Disease Prevalence
5.4.3.3. Competitive Scenario
5.4.3.4. Regulatory Framework
5.4.3.5. Japan In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.4.4. China
5.4.4.1. Key Country Dynamics
5.4.4.2. Target Disease Prevalence
5.4.4.3. Competitive Scenario
5.4.4.4. Regulatory Framework
5.4.4.5. China In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.4.5. India
5.4.5.1. Key Country Dynamics
5.4.5.2. Target Disease Prevalence
5.4.5.3. Competitive Scenario
5.4.5.4. Regulatory Framework
5.4.5.5. India In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.4.6. Australia
5.4.6.1. Key Country Dynamics
5.4.6.2. Target Disease Prevalence
5.4.6.3. Competitive Scenario
5.4.6.4. Regulatory Framework
5.4.6.5. Australia In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.4.7. Thailand
5.4.7.1. Key Country Dynamics
5.4.7.2. Target Disease Prevalence
5.4.7.3. Competitive Scenario
5.4.7.4. Regulatory Framework
5.4.7.5. Thailand In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.4.8. South Korea
5.4.8.1. Key Country Dynamics
5.4.8.2. Target Disease Prevalence
5.4.8.3. Competitive Scenario
5.4.8.4. Regulatory Framework
5.4.8.5. South Korea In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.5. Latin America
5.5.1. SWOT Analysis
5.5.2. Latin America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.5.3. Brazil
5.5.3.1. Key Country Dynamics
5.5.3.2. Target Disease Prevalence
5.5.3.3. Competitive Scenario
5.5.3.4. Regulatory Framework
5.5.3.5. Brazil In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.5.4. Mexico
5.5.4.1. Key Country Dynamics
5.5.4.2. Target Disease Prevalence
5.5.4.3. Competitive Scenario
5.5.4.4. Regulatory Framework
5.5.4.5. Mexico In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.5.5. Argentina
5.5.5.1. Key Country Dynamics
5.5.5.2. Target Disease Prevalence
5.5.5.3. Competitive Scenario
5.5.5.4. Regulatory Framework
5.5.5.5. Argentina In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.6. MEA
5.6.1. SWOT Analysis
5.6.2. MEA In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.6.3. South Africa
5.6.3.1. Key Country Dynamics
5.6.3.2. Target Disease Prevalence
5.6.3.3. Competitive Scenario
5.6.3.4. Regulatory Framework
5.6.3.5. South Africa In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.6.4. Saudi Arabia
5.6.4.1. Key Country Dynamics
5.6.4.2. Target Disease Prevalence
5.6.4.3. Competitive Scenario
5.6.4.4. Regulatory Framework
5.6.4.5. Saudi Arabia In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.6.5. UAE
5.6.5.1. Key Country Dynamics
5.6.5.2. Target Disease Prevalence
5.6.5.3. Competitive Scenario
5.6.5.4. Regulatory Framework
5.6.5.5. UAE In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
5.6.6. Kuwait
5.6.6.1. Key Country Dynamics
5.6.6.2. Target Disease Prevalence
5.6.6.3. Competitive Scenario
5.6.6.4. Regulatory Framework
5.6.6.5. Kuwait In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Chapter 6. Competitive Landscape
6.1. Company Categorization
6.2. Strategy Mapping
6.3. Company Market Share Analysis, 2022
6.4. Company Profiles/Listing
6.4.1. Abbott
6.4.1.1. Overview
6.4.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.1.3. Product Benchmarking
6.4.1.4. Strategic Initiatives
6.4.2. Beckman Coulter Inc
6.4.2.1. Overview
6.4.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.2.3. Product Benchmarking
6.4.2.4. Strategic Initiatives
6.4.3. Eiken Chemical Co., Ltd.
6.4.3.1. Overview
6.4.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.3.3. Product Benchmarking
6.4.3.4. Strategic Initiatives
6.4.4. Epigenomics
6.4.4.1. Overview
6.4.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.4.3. Product Benchmarking
6.4.4.4. Strategic Initiatives
6.4.5. Sysmex Corporation
6.4.5.1. Overview
6.4.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.5.3. Product Benchmarking
6.4.5.4. Strategic Initiatives
6.4.6. Siemens Healthcare GmbH
6.4.6.1. Overview
6.4.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.6.3. Product Benchmarking
6.4.6.4. Strategic Initiatives
6.4.7. Quest Diagnostics Incorporated
6.4.7.1. Overview
6.4.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.7.3. Product Benchmarking
6.4.7.4. Strategic Initiatives
6.4.8. OncoCyte Corporation
6.4.8.1. Overview
6.4.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.8.3. Product Benchmarking
6.4.8.4. Strategic Initiatives
6.4.9. Merck KGaA
6.4.9.1. Overview
6.4.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.9.3. Product Benchmarking
6.4.9.4. Strategic Initiatives
6.4.10. Immunostics Inc.
6.4.10.1. Overview
6.4.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.10.3. Product Benchmarking
6.4.10.4. Strategic Initiatives
6.4.11. Kyowa Kirin Co. Ltd.
6.4.11.1. Overview
6.4.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.11.3. Product Benchmarking
6.4.11.4. Strategic Initiatives
6.4.12. Randox Laboratories Ltd.
6.4.12.1. Overview
6.4.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.12.3. Product Benchmarking
6.4.12.4. Strategic Initiatives
6.4.13. R-Biopharm AG
6.4.13.1. Overview
6.4.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
6.4.13.3. Product Benchmarking
6.4.13.4. Strategic Initiatives
List of Tables
Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 Global In-vitro Colorectal Cancer Screening Tests Market, By Region, 2018 - 2030 (USD Million)
Table 4 Global In-vitro Colorectal Cancer Screening Tests Market, By Test Type, 2018 - 2030 (USD Million)
Table 5 North America In-vitro Colorectal Cancer Screening Tests Market, By Country, 2018 - 2030 (USD Million)
Table 6 North America In-vitro Colorectal Cancer Screening Tests Market, By Test Type, 2018 - 2030 (USD Million)
Table 7 U.S. America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 8 Canada America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 9 Europe America In-vitro Colorectal Cancer Screening Tests Market, by country, 2018 - 2030 (USD Million)
Table 10 Europe America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 11 UK America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 12 Germany America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 13 France America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 14 Italy America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 15 Spain America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 16 Sweden America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 17 Norway America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 18 Russia America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD)
Table 19 Denmark America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 20 Netherlands America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD)
Table 21 Asia Pacific America In-vitro Colorectal Cancer Screening Tests Market, by country, 2018 - 2030 (USD Million)
Table 22 Asia Pacific America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 23 Japan America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 24 China America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 25 India America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 26 Australia America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 27 Thailand America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 28 South Korea America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 29 Latin America In-vitro Colorectal Cancer Screening Tests Market, by country, 2018 - 2030 (USD Million)
Table 30 Latin America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 31 Brazil America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 32 Mexico America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 33 Argentina America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 34 Middle East & Africa America In-vitro Colorectal Cancer Screening Tests Market, by country, 2018 - 2030 (USD Million)
Table 35 Middle East & Africa America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 36 South Africa America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 37 Saudi Arabia America In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 38 UAE In-vitro Colorectal Cancer Screening Tests Market, by Test Type, 2018 - 2030 (USD Million)
Table 39 UAE In-vitro Colorectal Cancer Screening Tests Market, by application, 2018 - 2030 (USD)
Table 40 Kuwait America In-vitro Colorectal Cancer Screening Tests Market, by application, 2018 - 2030 (USD)
List of Figures
Fig. 1 Market Research Process
Fig. 2 Information Procurement
Fig. 3 Primary Research Pattern
Fig. 4 Market Research Approaches
Fig. 5 Value Chain-Based Sizing & Forecasting
Fig. 6 Market Formulation & Validation
Fig. 7 In-vitro Colorectal Cancer Screening Tests Market Segmentation
Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
Fig. 11 Penetration & Growth Prospect Mapping
Fig. 12 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 13 Porter’s Five Forces Analysis
Fig. 14 In-vitro colorectal cancer screening tests market: Test type outlook and key takeaways
Fig. 15 In-vitro colorectal cancer screening tests market: Test type movement analysis & market share 2022 & 2030
Fig. 16 Global fecal occult blood tests market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 17 Global guaiac FOB stool tests market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 18 Immuno-FOB agglutination tests market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 19 Lateral flow immuno-FOB tests market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 20 Immuno-FOB ELISA tests market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 21 Global biomarker tests market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 22 Tumor M2-PK stool tests market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 23 Transferrin assays market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 24 Global CRC DNA screening tests market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 25 Methylated gene testing market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 26 Panel DNA tests market estimates and forecast, 2018 - 2030 (USD Million)
Fig. 27 Regional Marketplace: Key Takeaways
Fig. 28 Regional Outlook, 2022 & 2030
Fig. 29 Regional Market Dashboard
Fig. 30 Regional Market Place: Key Takeaways
Fig. 31 North America, SWOT Analysis
Fig. 32 Europe, SWOT Analysis
Fig. 33 Asia Pacific, SWOT Analysis
Fig. 34 Latin America, SWOT Analysis
Fig. 35 MEA, SWOT Analysis
Fig. 36 North America
Fig. 37 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
Fig. 38 U.S. Key Country Dynamics
Fig. 39 U.S. America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 40 Canada Key Country Dynamics
Fig. 41 Canada America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 42 Europe America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 43 UK Key Country Dynamics
Fig. 44 UK America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 45 Germany Key Country Dynamics
Fig. 46 Germany America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 47 France Key Country Dynamics
Fig. 48 France America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 49 Italy Key Country Dynamics
Fig. 50 Italy America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 51 Spain Key Country Dynamics
Fig. 52 Spain America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 53 Sweden Key Country Dynamics
Fig. 54 Sweden America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 55 Norway Key Country Dynamics
Fig. 56 Norway America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 57 Denmark Key Country Dynamics
Fig. 58 Denmark America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 59 Russia Key Country Dynamics
Fig. 60 Russia America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 61 Netherlands Key Country Dynamics
Fig. 62 Netherlands America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 63 Asia Pacific America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 64 Japan Key Country Dynamics
Fig. 65 Japan America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 66 China Key Country Dynamics
Fig. 67 China America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 68 India Key Country Dynamics
Fig. 69 India America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 70 Australia Key Country Dynamics
Fig. 71 Australia America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 72 Thailand Key Country Dynamics
Fig. 73 Thailand America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 74 South Korea Key Country Dynamics
Fig. 75 South Korea America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 76 Latin America America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 77 Brazil Key Country Dynamics
Fig. 78 Brazil America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 79 Mexico Key Country Dynamics
Fig. 80 Mexico America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 81 Argentina Key Country Dynamics
Fig. 82 Argentina America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 83 Middle East and Africa America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 84 South Africa Key Country Dynamics
Fig. 85 South Africa America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 86 Saudi Arabia Key Country Dynamics
Fig. 87 Saudi Arabia America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 88 UAE Key Country Dynamics
Fig. 89 UAE America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 90 Kuwait Key Country Dynamics
Fig. 91 Kuwait America In-vitro Colorectal Cancer Screening Tests Market, 2018 - 2030 (USD Million)
Fig. 92 Strategy Mapping

Companies Mentioned

  • Abbott
  • Beckman Coulter Inc
  • Eiken Chemical Co., Ltd.
  • Epigenomics
  • Sysmex Corporation
  • Siemens Healthcare GmbH
  • Quest Diagnostics Incorporated
  • OncoCyte Corporation
  • Merck KGaA
  • Immunostics Inc.
  • Kyowa Kirin Co. Ltd.
  • Randox Laboratories Ltd.
  • R-Biopharm AG

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages129
PublishedSeptember 2023
Forecast Period2022 - 2030
Estimated Market Value ( USD ) in 2022 $ 864.55 Million
Forecasted Market Value ( USD ) by 2030 $ 1120 Million
Compound Annual Growth Rate3.0%
Regions CoveredGlobal
No. of Companies Mentioned13

Related Topics

Related Reports

In-vitro Colorectal Cancer Screening Tests Market Report by Product, Imaging Type, End User, and Region 2024-2032 - Product Image

In-vitro Colorectal Cancer Screening Tests Market Report by Product, Imaging Type, End User, and Region 2024-2032

  • Report
  • 143 Pages
  • Global
From
In-Vitro Colorectal Cancer Screening Tests Market Report and Forecast 2024-2032 - Product Image

In-Vitro Colorectal Cancer Screening Tests Market Report and Forecast 2024-2032

  • Report
  • 140 Pages
  • Global
From
in-Vitro Colorectal Cancer Screening Tests - Global Strategic Business Report - Product Image

in-Vitro Colorectal Cancer Screening Tests - Global Strategic Business Report

  • Report
  • 193 Pages
  • Global
From
In-vitro Colorectal Cancer Screening Tests Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

In-vitro Colorectal Cancer Screening Tests Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 180 Pages
  • Global
From
2024 Global Occult Blood Testing Market: US, Europe, Japan - Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Emerging Opportunities - Product Image

2024 Global Occult Blood Testing Market: US, Europe, Japan - Supplier Shares and Strategies, Volume and Sales Segment Forecasts, Emerging Opportunities

  • Report
  • 243 Pages
  • Europe, Global, Japan, ... Europe, Global, Japan, United States
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.